The oncologist

Keyphrases

Publications

2023

Karin Purshouse, John P Thomson, Mahéva Vallet, Lorna Alexander, Isaac Bonisteel, Maree Brennan, David A Cameron, Jonine D Figueroa, Elizabeth Furrie, Pamela Haig, Mattea Heck, Hugh McCaughan, Paul Mitchell, Heather McVicars, Lorraine Primrose, Ines Silva, Kate Templeton, Natalie Wilson, Peter S Hall
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment. The oncologist (2023)
D Max Smith, William D Figg
Evidence Regarding Pharmacogenetics in Pain Management and Cancer. The oncologist (2023)
Javier Muñoz, Shayna Sarosiek, Jorge J Castillo
Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The oncologist (2023)
Natalie Tse, Ruth M Parks, Holly M Holmes, Kwok-Leung Cheung
The Association Between Medication Use in Older Women with Early-Stage Operable Primary Breast Cancer and Decision Regarding Primary Treatment. The oncologist (2023)
Silvia Novello, Raffaele Califano, Niels Reinmuth, Antonella Tamma, Tarun Puri
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape. The oncologist (2023)
Javier Muñoz, Shayna Sarosiek, Jorge J Castillo
Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The oncologist (2023)
Bruce C Tiu, Ian A Strohbehn, Sophia Zhao, Tianqi Ouyang, Paul Hanna, Qiyu Wang, Shruti Gupta, David E Leaf, Kerry L Reynolds, Meghan E Sise
Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. The oncologist (2023)
Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. The oncologist (2023)
Srivandana Akshintala, Nicole C Mallory, Yao Lu, Karla V Ballman, Scott M Schuetze, Rashmi Chugh, Robert G Maki, Denise K Reinke, Brigitte C Widemann, Ae Rang Kim
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. The oncologist (2023)
Yan-Ling Li, Li-Ze Wang, Qing-Lei Shi, Ying-Jian He, Jin-Feng Li, Hai-Tao Zhu, Tian-Feng Wang, Xiao-Ting Li, Zhao-Qing Fan, Tao Ouyang, Ying-Shi Sun
CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study. The oncologist (2023)
Brian Hemendra Ramnaraign, Oliver Sartor
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. The oncologist (2023)
Grace N Dodoo, Brian Sandeep De, Sunyoung S Lee, Joseph Abi Jaoude, Jean-Nicholas Vauthey, Ching-Wei D Tzeng, Hop S Tran Cao, Kalman A Katlowitz, Jacob J Mandel, Thomas H Beckham, Bruce D Minsky, Grace L Smith, Emma B Holliday, Albert C Koong, Prajnan Das, Cullen M Taniguchi, Milind Javle, Eugene Jon Koay, Ethan Bernard Ludmir
Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. The oncologist (2023)
Kimberley J Perez, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A Meyerhardt, Douglas Rubinson, Matthew B Yurgelun, Wolfram Goessling, Bruce J Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R Pitarresi, Andrew J Aguirre, Michael Needle, Anil K Rustgi, Brian M Wolpin
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. The oncologist (2023)
Nuo Shi, Arkers Kwan Ching Wong, Frances-Kam-Yuet Wong, Liyan Sha
Mobile Health Application-Based Interventions to Improve Self-management of Chemotherapy-Related Symptoms Among People with Breast Cancer Who Are Undergoing Chemotherapy: A Systematic Review. The oncologist (2023)
Julia Coelho França Quintanilha, Ryon P Graf, Geoffrey R Oxnard
BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer. The oncologist (2023)
Fangcen Liu, Fangfang Zhong, Huan Wu, Keying Che, Jiaochun Shi, Nandie Wu, Yao Fu, Yue Wang, Jing Hu, Xiaoping Qian, Xiangshan Fan, Weifeng Wang, Jia Wei
Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers. The oncologist (2023)
Francis Ho, Alfred Kow, Wan Chin Lim, Matthew Zhixuan Chen, Nydia Camelia Mohd Rais, Natalie Mun Wai Ling, Melissa Ooi, Jing Yu Ng, Yean Shin Ng, Meiling Chun, Yao Yao, Noorhanah Mohd Said, Wan Nghee Eng, Wen Meei Chen, Vivian Luah, Yijun Loy, Jiexin Ong, Wei Yee Wong, Beatriz Korc-Grodzicki, Stuart M Lichtman, Angela Pang
Feasibility of a Geriatric Oncology Longitudinal End to End (GOLDEN) Program in a Tertiary Cancer Center in Singapore. The oncologist (2023)
Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53. The oncologist (2023)
Vishal R Patel, Thomas B Cwalina, Arjun Gupta, Nico Nortjé, Samyukta Mullangi, Ravi B Parikh, Ya Chen Tina Shih, S M Qasim Hussaini
Oncologist Participation and Performance in the Merit-Based Incentive Payment System. The oncologist (2023)
Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo G De Braud, Ravit Geva, Mark T J van Bussel, Katia Fiorella Dotti, Elena Elez, María J de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The oncologist (2023)

volume 28, number 1, 2023

Susan E Bates
Back to the Future, II. The oncologist 28 (1) (2023)
Susan E Bates
Back to the Future, II. The oncologist 28 (1) (2023)
Susan E Bates
Back to the Future, II. The oncologist 28 (1) (2023)

volume 28, number 2, 2023

Surbhi Bansil, Anthony Silva, Alana Taniguchi, Christina Wiedmer, Mayumi Fernandez, Ian Pagano, Koah Vierkoetter, Jeffrey Killeen, Jami Fukui
Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. The oncologist 28 (2) (2023)
Eric M Lander, Katherine C Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G Abramson
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. The oncologist 28 (2) (2023)
Katrina Woodford, Kendrick Koo, John Reynolds, Robert G Stirling, Susan V Harden, Margaret Brand, Sashendra Senthi
Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis. The oncologist 28 (2) (2023)
Eric M Lander, Katherine C Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G Abramson
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. The oncologist 28 (2) (2023)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist 28 (2) (2023)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist 28 (2) (2023)
Alexander I Spira, Michael S Wertheim, Edward J Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L Gulley, Edmund S Kopetz
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. The oncologist 28 (2) (2023)
Surbhi Bansil, Anthony Silva, Alana Taniguchi, Christina Wiedmer, Mayumi Fernandez, Ian Pagano, Koah Vierkoetter, Jeffrey Killeen, Jami Fukui
Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. The oncologist 28 (2) (2023)
Eric M Lander, Katherine C Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G Abramson
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. The oncologist 28 (2) (2023)
Alexander I Spira, Michael S Wertheim, Edward J Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L Gulley, Edmund S Kopetz
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. The oncologist 28 (2) (2023)
Katrina Woodford, Kendrick Koo, John Reynolds, Robert G Stirling, Susan V Harden, Margaret Brand, Sashendra Senthi
Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis. The oncologist 28 (2) (2023)
Jamie O Brett, Lauren L Ritterhouse, Erik T Newman, Kelly E Irwin, Megan Dawson, Lianne Y Ryan, Laura M Spring, Miguel N Rivera, Jochen K Lennerz, Dora Dias-Santagata, Leif W Ellisen, Aditya Bardia, Seth A Wander
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series. The oncologist 28 (2) (2023)

volume 28, number 3, 2023

Julia Coelho França Quintanilha, Ryon P Graf, Geoffrey R Oxnard
BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer. The oncologist 28 (3) (2023)
Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica
Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The oncologist 28 (3) (2023)
Fangcen Liu, Fangfang Zhong, Huan Wu, Keying Che, Jiaochun Shi, Nandie Wu, Yao Fu, Yue Wang, Jing Hu, Xiaoping Qian, Xiangshan Fan, Weifeng Wang, Jia Wei
Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers. The oncologist 28 (3) (2023)
Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo G De Braud, Ravit Geva, Mark T J van Bussel, Katia Fiorella Dotti, Elena Elez, María J de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The oncologist 28 (3) (2023)
Lewis Zhichang Shi, Hongxing Shen, Oluwagbemiga A Ojo, James A Bonner
HiJAKing Immunotherapy-Resistant Melanoma for a Cure. The oncologist 28 (3) (2023)
Luis Meza, David F McDermott, Bernard Escudier, Thomas E Hutson, Camillo Porta, Elena Verzoni, Michael B Atkins, Vijay Kasturi, Sumanta K Pal, Brian Rini
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. The oncologist 28 (3) (2023)
D Max Smith, William D Figg
Evidence Regarding Pharmacogenetics in Pain Management and Cancer. The oncologist 28 (3) (2023)
Fabrice Barlesi, Nicolas Isambert, Enriqueta Felip, Byoung Chul Cho, Dae Ho Lee, Julio Peguero, Guy Jerusalem, Nicolas Penel, Esma Saada-Bouzid, Pilar Garrido, Christoph Helwig, George Locke, Laureen S Ojalvo, James L Gulley
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The oncologist 28 (3) (2023)
Adrienne Nedved, Kami Maddocks, Grzegorz S Nowakowski
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The oncologist 28 (3) (2023)
Ivo Abraham
Trends, Changes, and Disruptions: The Fragile Economics of Cancer Treatments. The oncologist 28 (3) (2023)
Karin Purshouse, John P Thomson, Mahéva Vallet, Lorna Alexander, Isaac Bonisteel, Maree Brennan, David A Cameron, Jonine D Figueroa, Elizabeth Furrie, Pamela Haig, Mattea Heck, Hugh McCaughan, Paul Mitchell, Heather McVicars, Lorraine Primrose, Ines Silva, Kate Templeton, Natalie Wilson, Peter S Hall
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment. The oncologist 28 (3) (2023)
Rudolph Navari, Gary Binder, Alex Molasiotis, Jørn Herrstedt, Eric J Roeland, Kathryn J Ruddy, Thomas W LeBlanc, Dwight D Kloth, Kelsey A Klute, Eros Papademetriou, Luke Schmerold, Lee Schwartzberg
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. The oncologist 28 (3) (2023)
Natalie Tse, Ruth M Parks, Holly M Holmes, Kwok-Leung Cheung
The Association Between Medication Use in Older Women with Early-Stage Operable Primary Breast Cancer and Decision Regarding Primary Treatment. The oncologist 28 (3) (2023)
Georges Azzi, Mehrad Tavallai, Vasily N Aushev, Allyson Koyen Malashevich, Gregory P Botta, Mohamedtaki A Tejani, Diana Hanna, Shifra Krinshpun, Meenakshi Malhotra, Adham Jurdi, Alexey Aleshin, Pashtoon Murtaza Kasi
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The oncologist 28 (3) (2023)
Richard T Penson, Allison J Ambrosio, Christin A Whalen, Carolyn N Krasner, Panagiotis A Konstantinopoulos, Charles Bradley, Ursula A Matulonis, Michael J Birrer
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. The oncologist 28 (3) (2023)